In the crigler–najjar syndrome market, advancements in gene therapy offer promising solutions. These innovative treatments aim to correct the underlying genetic defect, providing hope for patients by potentially eliminating the need for lifelong phototherapy. Such progress improves quality of life and also signifies a significant step forward in managing this rare genetic disorder.
Frequently Asked Questions
The market is segmented based on Global Crigler–Najjar Syndrome Market Segmentation, By Drugs (Bilirubin Chelators, Ursodeoxycholic Acid and Others),Treatment (Surgery, Drugs, and Others), Mode of Administration (Injectable, Oral, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), End User (Hospitals, Homecare, Specialty Clinics, and Others) – Industry Trends and Forecast to 2031
.
The Global Criglernajjar Syndrome Market size was valued at USD 981.23 USD Million in 2023.
The Global Criglernajjar Syndrome Market is projected to grow at a CAGR of 7.84% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
